Waning of 2-Dose BNT162b2 and mRNA-1273 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Accounting for Depletion-of-Susceptibles Bias
American Journal of Epidemiology · 2023
DOI: 10.1093/aje/kwad017 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Epidemiology, 2023. Verfasst von Kristin L Andrejko und 12 weiteren Autor:innen. Hauptthemen laut MEDLINE: 2019-nCoV Vaccine mRNA-1273, COVID-19. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Concerns about the duration of protection conferred by coronavirus disease 2019 (COVID-19) vaccines have arisen in postlicensure evaluations. “Depletion of susceptibles,” a bias driven by differential accrual of infection among vaccinated and unvaccinated individuals, may obscure vaccine effectiveness (VE) estimates, hindering interpretation. We enrolled California residents who received molecular SARS-CoV-2 tests in a matched, test-negative design, case-control study to estimate VE of mRNA-based COVID-19 vaccines between February 23 and December 5, 2021. We analyzed waning protection following 2 vaccine doses using conditional logistic regression models. Additionally, we used data from a population-based serological study to adjust for “depletion-of-susceptibles” bias and estimated VE for 3 doses, by time since second dose receipt. Pooled VE of BNT162b2 and mRNA-1273 against symptomatic SARS-CoV-2 infection was 91.3% (95% confidence interval (CI): 83.8, 95.4) at 14 days after second-dose receipt and declined to 50.8% (95% CI: 19.7, 69.8) at 7 months. Adjusting for depletion-of-susceptibles bias, we estimated VE of 53.2% (95% CI: 23.6, 71.2) at 7 months after primary mRNA vaccination series. A booster dose of BN162b2 or mRNA-1273 increased VE to 95.0% (95% CI: 82.8, 98.6). These findings confirm that observed waning of protection is not attributable to epidemiologic bias and support ongoing efforts to administer additional vaccine doses to mitigate burden of COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Förderung
- NIAID NIH HHS
Zitieren
APA
Andrejko, K. L., Pry, J. M., Myers, J. F., Mehrotra, M., Lamba, K., Lim, E., Fukui, N., DeGuzman, J. L., Openshaw, J., Watt, J., Jain, S., Lewnard, J. A., & Covid-Case-Control Study Team, O. B. O. T. C. (2023). Waning of 2-Dose BNT162b2 and mRNA-1273 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Accounting for Depletion-of-Susceptibles Bias. American Journal of Epidemiology. https://doi.org/10.1093/aje/kwad017
Vancouver
Andrejko KL, Pry JM, Myers JF, Mehrotra M, Lamba K, Lim E, et al. Waning of 2-Dose BNT162b2 and mRNA-1273 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Accounting for Depletion-of-Susceptibles Bias. American Journal of Epidemiology. 2023. doi:10.1093/aje/kwad017
BibTeX
@article{Andrejko2023,
author = {Andrejko, Kristin L and Pry, Jake M and Myers, Jennifer F and Mehrotra, Megha and Lamba, Katherine and Lim, Esther and Fukui, Nozomi and DeGuzman, Jennifer L and Openshaw, John and Watt, James and Jain, Seema and Lewnard, Joseph A and Covid-Case-Control Study Team, On Behalf Of The California},
title = {Waning of 2-Dose BNT162b2 and mRNA-1273 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Accounting for Depletion-of-Susceptibles Bias},
journal = {American Journal of Epidemiology},
year = {2023},
doi = {10.1093/aje/kwad017}
}
EUVIMED